Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Frost, S ^a,b   Kanagasingam, Y ^a   Sohrabi, H ^c   Vignarajan, J ^a   Bourgeat, P ^a   Salvado, O ^a   Villemagne, V ^a,d,e   Rowe, C C ^d   Lance MacAulay, S ^a   Szoeke, C ^a,f   Ellis, K A ^e,f   Ames, D ^e,f   Masters, C L ^e   Rainey Smith, S ^c   Martins, R N ^c  

^a CSIRO   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c EDITH COWAN UNIVERSITY   (Australia)

^d AUSTIN HEALTH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

Author keywords

aging; Alzheimer's; eye; retina; screening; vasculature

Indexed keywords

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; HUMAN; HYPERTENSION; LASER DOPPLER FLOWMETRY; MAJOR CLINICAL STUDY; MALE; NEOCORTEX; NEUROIMAGING; OPTICAL COHERENCE TOMOGRAPHY; RETINA BLOOD VESSEL; RETINA DEGENERATION; SCREENING; SENSITIVITY AND SPECIFICITY; SMOKING; TREATMENT RESPONSE; VISUAL SYSTEM PARAMETERS; ANALYSIS OF VARIANCE; AUSTRALIA; BRAIN; COHORT ANALYSIS; DISEASE COURSE; METHODOLOGY; PHOTOGRAPHY; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; RETINA ARTERY; RETINA DISEASE; RETINA VEIN; SCINTISCANNING;

BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; AUSTRALIA; BIOLOGICAL MARKERS; BRAIN; COHORT STUDIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; PHOTOGRAPHY; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; RETINAL ARTERY; RETINAL DISEASES; RETINAL VEIN;

MLCS; MLOWN;

EID: 84875148881     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.150     Document Type: Article

References (72)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
2. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML et al. Genomewide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-1093.
3. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-1099.
4. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008; 9: 768-778.
5. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923. (Pubitemid 23275809)
6. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094-2103. (Pubitemid 37430211)
7. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-519. (Pubitemid 43358072)
8. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725. (Pubitemid 46763260)
9. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-1283.
10. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66: 1469-1475.
11. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20: 6-15. (Pubitemid 44356888)
12. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144.
13. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130(Pt 11): 2837-2844. (Pubitemid 350033975)
14. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
15. Frost S, Martins RN, Kanagasingam Y. Ocular biomarkers for early detection of Alzheimer's disease. J Alzheimers Dis 2010; 22: 1-16.
16. Katz B, Rimmer S. Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol 1989; 34: 31-43. (Pubitemid 19201303)
17. Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ. Assessment of visual impairment in patients with Alzheimer's disease. Am J Ophthalmol 1987; 104: 113-120. (Pubitemid 17119032)
18. Trick GL, Trick LR, Morris P, Wolf M. Visual field loss in senile dementia of the Alzheimer's type. Neurology 1995; 45: 68-74.
19. Whittaker KW, Burdon MA, Shah P. Visual field loss and Alzheimer's disease. Eye (Lond) 2002; 16: 206-208. (Pubitemid 34537706)
20. Pache M, Smeets CH, Gasio PF, Savaskan E, Flammer J, Wirz-Justice A et al. Colour vision deficiencies in Alzheimer's disease. Age Ageing 2003; 32: 422-426. (Pubitemid 36926608)
21. Cronin-Golomb A, Sugiura R, Corkin S, Growdon JH. Incomplete achromatopsia in alzheimer's disease. Neurobiol Aging 1993; 14: 471-477. (Pubitemid 23270011)
22. Lakshminarayanan V, Lagrave J, Kean ML, Dick M, Shankle R. Vision in dementia: contrast effects. Neurol Res 1996; 18: 9-15. (Pubitemid 26060382)
23. Crow RW, Levin LB, LaBree L, Rubin R, Feldon SE. Sweep visual evoked potential evaluation of contrast sensitivity in Alzheimer's dementia. Invest Ophthalmol Vis Sci 2003; 44: 875-878. (Pubitemid 36159740)
24. Nissen MJ, Corkin S, Buonanno FS, Growdon JH, Wray SH, Bauer J. Spatial vision in Alzheimer's disease. General findings and a case report. Arch Neurol 1985; 42: 667-671.
25. Mendola JD, Cronin-Golomb A, Corkin S, Growdon JH. Prevalence of visual deficits in Alzheimer's disease. Optom Vis Sci 1995; 72: 155-167.
26. Schlotterer G, Moscovitch M, Crapper-McLachlan D. Visual processing deficits as assessed by spatial frequency contrast sensitivity and backward masking in normal ageing and Alzheimer's disease. Brain 1984; 107(Pt 1): 309-325.
27. Mielke R, Kessler J, Fink G, Herholz K, Heiss WD. Dysfunction of visual cortex contributes to disturbed processing of visual information in Alzheimer's disease. Int J Neurosci 1995; 82: 1-9.
28. Morrison JH, Hof PR, Bouras C. An anatomic substrate for visual disconnection in Alzheimer's disease. Ann NY Acad Sci 1991; 640: 36-43.
29. Wong-Riley M, Antuono P, Ho KC, Egan R, Hevner R, LieblWet al. Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. Vision Res 1997; 37: 3593-3608. (Pubitemid 27491637)
30. Gilmore GC, Wenk HE, Naylor LA, Koss E. Motion perception and Alzheimer's disease. J Gerontol 1994; 49: P52-P57. (Pubitemid 24100250)
31. Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer's disease. Ophthalmology 1990; 97: 9-17. (Pubitemid 20020620)
32. Fletcher WA, Sharpe JA. Smooth pursuit dysfunction in Alzheimer's disease. Neurology 1988; 38: 272-277. (Pubitemid 18036852)
33. Mendez MF, Tomsak RL, Remler B. Disorders of the visual system in Alzheimer's disease. J Clin Neuroophthalmol 1990; 10: 62-69. (Pubitemid 20115346)
34. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci 2007; 48: 2285-2289. (Pubitemid 351261307)
35. Tsai CS. Optic nerve head and nerve fiber layer in Alzheimer's disease. Arch Ophthalmol 1991; 109: 199.
36. Danesh-Meyer HV, Birch H, Ku JY, Carroll S, Gamble G. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology 2006; 67: 1852-1854. (Pubitemid 44900767)
37. Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer's Disease. Eur Neurol 2002; 47: 165-168. (Pubitemid 34253039)
38. Tamura H, Kawakami H, Kanamoto T, Kato T, Yokoyama T, Sasaki K et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neurol Sci 2006; 246: 79-83. (Pubitemid 43815345)
39. Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res 1989; 501: 364-372. (Pubitemid 19259642)
40. Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging 1996; 17: 385-395. (Pubitemid 26200415)
41. Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging 1996; 17: 377-384. (Pubitemid 26201356)
42. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med 1986; 315: 485-487. (Pubitemid 16034149)
43. Sadun AA, Bassi CJ. The visual system in Alzheimer's disease. Res Publ Assoc Res Nerv Ment Dis 1990; 67: 331-347.
44. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2007; 420: 97-99. (Pubitemid 46818666)
45. Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F. Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol 2001; 112: 1860-1867. (Pubitemid 32831524)
46. Iseri PK, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 2006; 26: 18-24. (Pubitemid 44502755)
47. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009; 21: 672-687.
48. Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74: 121-127.
49. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319. (Pubitemid 38269583)
50. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005; 25: 10598-10606. (Pubitemid 41681907)
51. Villemagne V, Pike K, Fodero-Tavoletti M, Jones G, McLean C, Hinton F et al. Age dependent prevalence of beta-amyloid positive 11C-PiB PET in healthy elderly subjects parallels neuropathology findings. J NUCL MED 2008; 49(MeetingAbstracts-1):34.
52. Cheung CY-L HsuW, Lee ML,Wang JJ, Mitchell P, Lau QP et al. A new method to measure peripheral retinal vascular caliber over an extended area. Microcirculation 2010; 17: 495-503.
53. Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, Cooper LS et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/ sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 1999; 106: 2269-2280. (Pubitemid 30191437)
54. Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, Klein BE. Revised formulas for summarizing retinal vessel diameters. Curr Eye Res 2003; 27: 143-149. (Pubitemid 37159478)
55. Mainster MA. The fractal properties of retinal vessels: embryological and clinical implications. Eye 1990; 4(Pt 1): 235-241. (Pubitemid 20304644)
56. Hart WE, Goldbaum M, Cote B, Kube P, Nelson MR. Measurement and classification of retinal vascular tortuosity. Int J Med Inform 1999; 53: 239-252. (Pubitemid 29101723)
57. Chapman N, Dell'omo G, Sartini MS, Witt N, Hughes A, Thom S et al. Peripheral vascular disease is associated with abnormal arteriolar diameter relationships at bifurcations in the human retina. Clin Sci (Lond) 2002; 103: 111-116.
58. King LA, Stanton AV, Sever PS, Thom SA, Hughes AD. Arteriolar length-diameter (L:D) ratio: A geometric parameter of the retinal vasculature diagnostic of hypertension. J Hum Hypertens 1996; 10: 417-418. (Pubitemid 26308465)
59. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate-a Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met 1995; 57: 289-300.
60. Sun C, Wang JJ, Mackey DA, Wong TY. Retinal vascular caliber: systemic, environmental, and genetic associations. Surv Ophthalmol 2009; 54: 74.
61. Alzheimer A. About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson). Alzheimer Dis Assoc Disord 1987; 1: 3-8.
62. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996; 46: 1592-1596. (Pubitemid 26185777)
63. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109: 813-836. (Pubitemid 34810776)
64. Vinters HV, Wang ZZ, Secor DL. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol 1996; 6: 179-195. (Pubitemid 26160505)
65. Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J Anat 2005; 206: 319-348. (Pubitemid 40542839)
66. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV,Miller CA, Ko MK, Black KL et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 2010; 54(Suppl 1): S204-S217.
67. de Jong FJ, Schrijvers EM, Ikram MK, Koudstaal PJ, de Jong PT, Hofman A et al. Retinal vascular caliber and risk of dementia: the Rotterdam study. Neurology 2011; 76: 816-821.
68. Ikram MK, Witteman JCM, Vingerling JR, Breteler MMB, Hofman A, de Jong PTVM. Retinal vessel diameters and risk of hypertension-the Rotterdam Study. Hypertension 2006; 47: 189-194. (Pubitemid 43189762)
69. Kawasaki R, Cheung N, Wang JJ, Klein R, Klein BEK, Cotch MF et al. Retinal vessel diameters and risk of hypertension: the Multiethnic Study of Atherosclerosis. J Hypertens 2009; 27: 2386-2393.
70. Avakian A, Kalina RE, Sage EH, Rambhia AH, Elliott KE, Chuang EL et al. Fractal analysis of region-based vascular change in the normal and non-proliferative diabetic retina. Curr Eye Res 2002; 24: 274-280. (Pubitemid 35155743)
71. Daxer A. Fractal analysis of new vessels in diabetic-retinopathy. Invest Ophthalmol Vis Sci 1993; 34: 718-718.
72. Wong TY, Wang JJ, Rochtchina E, Klein R, Mitchell P. Does refractive error influence the association of blood pressure and retinal vessel diameters? The Blue Mountains Eye Study. Am J Ophthalmol 2004; 137: 1050-1055. (Pubitemid 38759353)